With the rise of various multi-drug resistance pathogenic bacteria, worldwide health care is under pressure to respond. Conventional antibiotics are failing and the development of novel classes or alternative strategies is a major priority. Antimicrobial peptides (AMPs) can not only kill multi-drug resistant bacteria, but also can be used synergistically with conventional antibiotics. We selected 30 short AMPs from different origins and measured their synergy in combination with Polymyxin B, Piperacillin, Ceftazidime, Cefepime, Meropenem, Imipenem, Tetracycline, Erythromycin, Kanamycin, Tobramycin, Amikacin, Gentamycin, and Ciprofloxacin. In total 403 unique combinations were tested against a multi-drug resistant Pseudomonas aeruginosa isolate (PA910). As a measure of the synergistic effects, fractional inhibitory concentrations (FICs) were determined using microdilution assays with FICs ranges between 0.25 and 2. A high number of combinations between peptides and Polymyxin B, Erythromycin and Tetracycline were found to be synergistic. Novel variants of Indolicidin also showed a high frequency in synergist interaction.
Introduction
Among the most serious problems health care is facing is the increased number of infections caused by antibiotic-resistant bacteria, which can no longer be treated with previously active antimicrobial agents. The World Health Organization (WHO) identified in 2013 the development of antibiotic resistance as one of the major global threats to human society and recommended intensive monitoring for the identification of critical hot spots, in order to reduce transmission. The global spread of antibiotic resistance is one of the most interesting examples of biological evolution. It is highly relevant to both human and animal health and welfare with a direct impact on society. The primary cause of this situation is the excessive use of antibiotics (Berendonk et al., 2015) . Although the environmental bacteria are most probably the original source of many antibiotic resistance genes found in bacterial pathogens, the impact of nosocomial resistance and transmission has greatly increased over the last half century (Bush et al., 2011) . The increased prevalence of antibiotic resistance in microbiota is due to four major reasons: i) horizontal transfer of antibiotic resistance genes, ii) the assortment of resistant bacteria due to selective pressures from antimicrobial usage, (iii) the bacterial ability for gene mutation and recombination (e.g. presence of mutator determinants) (Cantón and Morosini, 2011; Davies and Davies, 2010; Wright and Sutherland, 2007) and (iv) the dissemination of resistant organisms from human and animal commensals that have adapted to antibiotic treatment of the host. Importantly, we cannot exclude proliferation of antibiotic resistance due to the spread of resistant bacterial clones and their mobile genetic elements carrying antibiotic-resistance genes, this is due to spontaneous processes not necessarily linked with antibiotic resistance (Baquero et al., 2013; Kohanski et al., 2010; Seiler and Berendonk, 2012) . Though the over-use of antibiotics may select for resistant populations, other biotic and abiotic factors including physicochemical conditions, pollution, induction of stress responses, bacterial adaptation and phenotypic heterogeneity among others, can enhance the effect of selective pressure. Evidence has shown that even in sub-inhibitory concentration antibiotics may still exert their impact on microbial community (Andersson and Hughes, 2014 ).
The review on antimicrobial resistance chaired by Jim O'Neill, initiated by the UK prime minister in 2014, published 2016 estimates that by 2050 more people (10 million) will die each year from infections than current number of people who die from cancer (https://amrreview.org/Publications.html). In order to maintain modern medical standards of care, it is a matter of urgency that novel antimicrobials are discovered and developed, particularly those with novel modes of action, which are less likely to suffer cross-resistance to existing drugs. The WHO published a priority list in 2017 (http://www.who.int/news-room/detail/27-02-2017-who-publishes-list-ofbacteria-for-which-new-antibiotics-are-urgently-needed) of bacteria that are especially problematic, in order to provide information and focus for drug development projects. In the highest category is carbapenem-resistant Pseudomonas aeruginosa.
Pseudomonas aeruginosa is a rod-shaped, Gram-negative bacterium, which is naturally found in soil and water and therefore well adapted to humid environments. It is a clinically important, opportunistic pathogen, which may cause pneumonia and bacteraemia in the elderly or immuno-compromised hosts. It is responsible for chronic, destructive lung disease in patients suffering from cystic fibrosis (Bhagirath et al., 2016) . P. aeruginosa exhibits a higher intrinsic resistance to a number of antimicrobial agents compared to most other Gram-negative bacteria (Yoneda et al., 2005) . Additionally, rapid development of resistance to previously effective antimicrobials, such as fluoroquinolones, sulfonamides or macrolides has been observed (Breidenstein et al., 2011; Ellington and Woodford, 2006; Oh et al., 2003; Sköld, 2000) .
Unfortunately, there has been a significant reduction in the development of novel antimicrobial agents with many major pharmaceutical companies halting research in anti-infective agents. The fact there are very few new antimicrobial agents with a new mode of action increases the risk of a nightmare scenario where even "minor" infections could become serious health risks. As there is already only a limited number of anti-pseudomonal antibiotics and increasing prevalence of resistance, it is an important question as to whether potential new antibiotics with different modes of action also synergise with "old" antimicrobials, especially for multi-drug resistant (MDR) bacteria. Antimicrobial peptides (AMPs) are potential novel antimicrobial drugs with some much-desired features, for example low chance for development of resistance, fast acting, broad spectrum activity and active against MDR bacteria. So far only a few have been enrolled in clinical studies (Czaplewski et al., 2016; Greber and Dawgul, 2017) . In this study we investigated whether synergy exists between designed short, cationic AMPs and conventional antibiotics in MDR P. aeruginosa or not. Such a synergy could be a starting point for further optimization to re-use already clinically valuable antibiotics.
Material and Methods

Peptides and antibiotics
All peptides used in this study were purchased from the Brain-Research Centre at the University of British Columbia. Peptides were characterized and purified via high-performance liquid chromatography (HPLC), mass was confirmed by matrix assisted laser desorption time of flight (MALDI-TOF) mass spectroscopy. Purity of all peptides was greater than 90%.
All antibiotics were purchased from VWR, except Polymyxin B, which was purchased from SigmaAldrich.
Minimal inhibitory concentration (MIC)
We selected six different P. aeruginosa isolates that were described as multi-drug resistant and had been isolated from clinical or municipal waste water (Schwartz et al., 2006) . The MIC was determined in a microdilution assay using Mueller-Hinton broth (MH) following a previous published protocol (Wiegand et al., 2008) . Briefly, a twofold serial dilution of the antibiotics and peptides were prepared and added to a bacteria solution resulting in 2-5 10 5 CFU/ml. The microtiter plates (polypropylene, Corning) were incubated for 18 h at 37 °C and MIC were taken visually.
Fractional inhibitory concentration (FIC)
The checkerboard assay was used to determine the FICs, following the protocol described in Koneman's Color Atlas and Textbook of Diagnostic Microbiology (Winn Jr et al., 2006) . Briefly, combinations of peptides and antibiotics were prepared in 96 well plates (polypropylene, Corning) in a twofold dilution series. After the addition of a log-phase bacterial inoculum of 2-5 x 10 5 CFU/ml, plates were incubated at 37 °C for 18 h. The FICs were determined by visual inspection. The effects of the combinations were determined using the FICs. 
Results
First, we have determined the MIC values against a range of different antibiotics for all six strains of P. aeruginosa, that were described as multi-drug resistant and had been isolated from clinical or municipal waste water, in comparison with a sensitive wild type strain (PAO1), see A set of short peptides between 9 and 13 amino acids in length were selected from already published and from ongoing unpublished work (Cherkasov et The synergistic effects of combination of short antimicrobial peptides and conventional antibiotics 13 resulted in a complex pattern. There were peptides that show no synergistic effect, whilst others showed 14 a variety, similar to the tested antibiotics, see Figure 1A and B. 15 Table 3  24 25 Selected peptide-antibiotic combinations were tested three times to confirm first findings, see World Health Organization has declared it to be a "critical priority pathogen," on which research and 57 development of novel antibiotics should be focused (Tacconelli et al., 2018) . 58
We confirmed the described multi-drug resistance of P. aeruginosa strains that were isolated in clinical 59 and municipal waste water, see Table 1 The FICs between combinations of antibiotics and peptides show several enhanced synergistic effects 68 by using antibiotics in tandem with short AMPs. In general, the beta-lactams and beta-lactam like 69 antibiotics show the lowest amount of synergy, along with Ciprofloxacin, a gyrase inhibitor, which 70 also showed a rather low amount of synergy. Cefepime and Piperacillin showed no detectable synergy 71 at all. Whereas, antibiotics acting on the ribosome show a higher amount of synergy, with the highest 72 proportion of synergy observed with Polymyxin B, which acts on the cell wall and cell membrane. The 73 majority of the results were confirmed by three independent measurements of the selected 74 combinations. Some combinations however showed a larger FIC values as determined in the first 75 screen, this proving the importance of verification of FIC data (Hsieh et al., 1993) . 76
Polymyxin B binds to the lipid A portion of the lipopolysaccharides (LPS), to replace cationic ions like 77 Ca 2+ and Mg 2+ from the LPS layer (Morrison and Jacobs, 1976) . This process destabilizes the LPS 78 layer, leading to permeability changes and consequently to an "self-promoted uptake" (Hancock, 1997; 79 Hermsen et al., 2003) . This process destabilises the membrane and allows molecules to pass through 80 the membrane in both directions. It has been shown that Polymyxin Cefepime is a fourth-generation cephalosporin antibiotic that has an extended spectrum of activity 90 against Gram-positive and Gram-negative bacteria and is more stable as compared to third-generation 91 agents (Wynd and Paladino, 1996) . Cefepime has good activity against multi-drug resistant 92
Streptococcus pneumoniae. produced by Micromonospora purpurea and acts on the 30S subunit. It is highly active against Gram-120 negative bacteria and shows activity against some Gram-positive bacteria (Daniels et al., 1975) . 121
Amikacin is a semi-synthetic antibiotic based on Kanamycin A, both members of the class 122 aminoglycosides, which binds to the 30S subunit and 16 srRNA. Amikacin demonstrates a broad-123 spectrum activity towards Gram-negative bacteria, including pseudomonades and has some effects on 124
Gram-positive bacteria, including Staphylococcus aureus (Ristuccia and Cunha, 1985 
